Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model

Antimicrob Agents Chemother. 2009 Feb;53(2):805-7. doi: 10.1128/AAC.01009-08. Epub 2008 Nov 17.

Abstract

The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (10(8) CFU/ml). A high bacterial load of >10(5) CFU/ml persisted for all strains with doses up to 5 g every 12 h against high inoculum amounts. No change in the vancomycin MIC was detected in any isolate at a moderate inoculum amount (10(6) CFU/ml), and bactericidal activity occurred only against the non-hVISA isolate (time to 99% kill, 7.5 h; P = 0.001).

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Colony Count, Microbial
  • Computer Simulation
  • Humans
  • Microbial Sensitivity Tests
  • Staphylococcal Infections / microbiology
  • Staphylococcus aureus / drug effects*
  • Vancomycin / pharmacology*
  • Vancomycin Resistance / drug effects*

Substances

  • Anti-Bacterial Agents
  • Vancomycin